Avalo Therapeutics

Avalo Therapeutics(AVTX)

WAYNE, PA
Biotechnology

Focus: Small molecules for neuro / psychiatric disorders

Avalo Therapeutics is a life sciences company focused on Small molecules for neuro / psychiatric disorders.

Psychiatry
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADH
Attention Deficit Disorder With Hyperactivity
N/A
Clinical Trials (1)
NCT02811211A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD
N/A
A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR
Attention Deficit Hyperactivity Disorder
N/A
Clinical Trials (1)
NCT03233867A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations
N/A
Clinical Trials (1)
NCT02895906Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions
Phase 1
Clinical Trials (1)
NCT02286817Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
Phase 1
Phase 1
Clinical Trials (1)
NCT04994002A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations
Phase 1
Clinical Trials (1)
NCT03006367Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD
Phase 1
Phase 1
Clinical Trials (1)
NCT04671251Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1
Phase 1
Clinical Trials (1)
NCT01579526A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT03169894Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
Phase 1
Phase 2
Clinical Trials (1)
NCT02468414TARGTEPO Treatment for Anemia in PD US Trial
Phase 2
Clinical Trials (1)
NCT02459236A Study of Intermittent Doses of CERC-301 in MDD
Phase 2
Clinical Trials (1)
NCT03609619PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations
Phase 2
Phase 2
Clinical Trials (1)
NCT04412057Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
Phase 2
AVTX-009 Regimen 1
Hidradenitis Suppurativa
Phase 2
Clinical Trials (1)
NCT06603077A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 2
Clinical Trials (1)
NCT03265119PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations
Phase 2
Clinical Trials (1)
NCT01941043A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment
Phase 2
Clinical Trials (1)
NCT01703923An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
Phase 2
Phase 2
Clinical Trials (1)
NCT01597349Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection
Phase 2
Clinical Trials (1)
NCT05288504A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
Phase 2
Clinical Trials (1)
NCT02777931Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 20 clinical trials
SEC Filings: 2 available

Financials (FY2024)

Revenue
$2M89%
R&D Spend
$14M(716%)56%
Net Income
-$32M
Cash
$7M